Quest PharmaTech Inc.

As of January 31, 2026, Quest PharmaTech Inc. carries a market capitalization of 5.92M, placing it among publicly traded companies globally. Its enterprise value stands at 6.91M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of January 31, 2026, Quest PharmaTech Inc. has 169.13M shares outstanding.

As of January 31, 2026, Quest PharmaTech Inc. trades at a trailing price-to-earnings ratio of 1.70.

As of January 31, 2026, Quest PharmaTech Inc. maintains a current ratio of 0.02, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.78, indicating elevated leverage, while an interest coverage ratio of -54.22 demonstrates limited ability to service its debt obligations.

Over the twelve months ended January 31, 2026, Quest PharmaTech Inc. posted a return on equity (ROE) of 14.05, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -3.23, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 13.40, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 13.56, useful for judging operating efficiency across full business cycles.

As of the close on October 20, 2026, Quest PharmaTech Inc.'s stock has declined approximately 50.00% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.03.

Over the twelve months ended January 31, 2026, Quest PharmaTech Inc. generated - - in revenue and converted that into 3.48M in net income, yielding earnings per share of 0.02. EBITDA reached -831,833.00, while operating income came in at -831,833.00.

As of January 31, 2026, Quest PharmaTech Inc. holds 14,363.00 in cash and equivalents against 1.00M in total debt, resulting in a net debt position of 985,637.00. Total book value stands at 26.43M, with working capital of -1.30M providing operational flexibility.

Quest PharmaTech Inc. produced -206,137.00 in operating cash flow over the twelve months ended January 31, 2026.

These figures cover the twelve months ended January 31, 2026. Free cash flow yield is negative at -3.48: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches - -, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Quest PharmaTech Inc. shareholders.

As of January 31, 2026, Quest PharmaTech Inc. has an Altman Z-Score of 1.72, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.